On August 15, 2025, Theravance Biopharma, Inc. entered into a settlement with Cipla regarding patent disputes over YUPELRI, allowing Cipla to sell a generic version starting April 23, 2039, pending review by U.S. regulators. This event is significant and has a neutral sentiment from an investor perspective.